Ibruxen (Ibrutinib), a generic version of Imbruvica, is a prescribed medication for treating specific cancers like Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma, and Marginal Zone Lymphoma (MZL). It's also used to address conditions such as Waldenstrom Macroglobulinemia and Chronic Graft-Versus-Host Disease (cGVHD). Ibruxen is manufactured by Everest Pharma Ltd. in Bangladesh.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Ibrutinib is a targeted cancer therapy used to treat various conditions, including:
There is limited information on the interaction of Ibruxen 140mg Capsules with alcohol. Please discuss with your doctor regarding the consumption of alcohol with Ibruxen 140mg Capsule
There is limited information available about the safety of Ibruxen 140mg Capsule in pregnant women. Thus, to avoid any risks to the developing baby, Ibruxen 140mg Capsule is not recommended for use in pregnancy.
No information is available if Ibruxen 140mg Capsule passes into human breast milk. It is recommended that breastfeeding women should not use this medicine.
Ibruxen 140mg Capsule may have a minor effect on driving ability. After taking this medicine, if you experience dizziness or weakness, then it is suggested that you do not drive.
Ibruxen140mg Capsule should be used with caution in patients with kidney diseases due to the increased risk of worsening the patient's condition. Close monitoring of kidney function, appropriate dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Ibruxen140mg Capsule should be used with caution in patients suffering from liver diseases due to the increased risk of worsening the patient's condition. Close monitoring of liver function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
It works by inhibiting the activity of BTK, a signaling molecule crucial for B-cell function, leading to decreased cancer cell proliferation and survival.
Adverse reactions include bleeding, infections, cytopenias, atrial fibrillation, hypertension, second primary malignancies, tumor lysis syndrome, diarrhea, and visual disturbances.
This medicine is used in the treatment of chronic lymphocytic leukemia, a type of blood cancer that affects white blood cells called lymphocytes.
This medicine is used to treat mantle cell lymphoma (a type of cancer that affects the lymph nodes) in patients who have not adequately responded to the previous therapy.
This medicine is used to treat Waldenstrom's macroglobulinemia (a type of cancer that starts in certain white blood cells called lymphocytes in the bone marrow) in patients who have not adequately responded to the previous therapy.
This medicine is used to treat marginal zone lymphoma in patients who have received therapy with a certain type of chemotherapy medication.
This medicine is used to treat chronic graft-versus-host disease (cGVHD) in patients who have not adequately responded to one or more lines of systemic therapy.
Ibrutinib functions as a small-molecule inhibitor of BTK. By forming a covalent bond with a cysteine residue in the BTK active site, it effectively suppresses BTK enzymatic activity. BTK plays a vital role in the signaling pathways of the B-cell antigen receptor (BCR) and cytokine receptors. Its role in signaling through B-cell surface receptors leads to the activation of pathways essential for B-cell trafficking, chemotaxis, and adhesion. Preclinical studies indicate that ibrutinib hampers malignant B-cell proliferation and survival both in vivo and in vitro, along with curtailing cell migration and substrate adhesion.
Dosage recommendations for Ibrutinib are as follows:
Mantle Cell Lymphoma and Marginal Zone Lymphoma: The recommended dose for MCL and MZL is 560 mg (four 140 mg capsules) taken orally once daily. This regimen should continue until disease progression or unacceptable levels of toxicity.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM): For CLL/SLL and WM, the recommended dose is 420 mg (three 140 mg capsules) taken orally once daily. This dosing schedule should be maintained until disease progression or unacceptable toxicity. In the case of CLL/SLL, when used in conjunction with bendamustine and rituximab, the prescribed dose is also 420 mg (three 140 mg capsules) orally once daily. This combination treatment should follow a 28-day cycle for up to 6 cycles, or as directed by a healthcare professional.
Special Populations:
Interactions with Other Medicines, Foods, and Drinks: Cancer medications like ibrutinib can interact with other medications and herbal products. It's important to inform your doctor or pharmacist about all the medications you are currently taking, including vitamins, herbal supplements, and over-the-counter remedies.
Hypersensitivity to the active substance or excipients.
Talk to your doctor if
Store below 30°C, protect from light and keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.